Matt Kelmon
Matt Kelmon
five next question stocks
There's no question that drug stocks are dirt-cheap but are they going to be dirt-cheap for the next five years?
bottom company continued cost cutting earnings help markets money room worst
Continued cost cutting is going to help the bottom line. The company is making money in one of the worst markets and there's room for earnings to go a lot higher.
looks spending
I am disappointed. It looks like they are doing a lot more spending than expected.